AMRX - Amneal Pharmaceuticals, Inc.
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
On September 28, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 3.7% to $20.50, reflecting strong price performance especially in the context of its 52-wee
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
On September 15, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 3.3% to $16.65. This decline comes amid a 52-week trading range of $9.49 to $19.26, indicat
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization.
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Arkadios Wealth Advisors purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 335,098 shares of the company's stock, valued at approximately $4,165,000. Arkadios Wealth Advisors owned approximately
Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.